



2  
0  
2  
5



36th Annual Meeting and  
Scientific Symposium

November 6-9  
San Francisco, CA

# 2025 Conference at a Glance



# Table of Contents

---

President's Welcome	3
About AAAP	4
Outstanding Achievement and Service Award	5
Schedule-at-a-Glance	6
Accreditation and Designation Statements	11
Symposia	12
Mini Symposium	28
Debate	30
Addiction Psychiatry Annual Review	36
Medical Update	41
Film and Media Workshop	42
Case Conference	43
Workshops	46
Papers	49
Awards	52
Promotional Sponsors and Exhibitors	57

# Welcome


## to the 35th AAAP Annual Meeting and Scientific Symposium!

On behalf of the AAAP Staff and Board of Directors, I would like to welcome you to the 36th AAAP Annual Meeting and Scientific Symposium. It's been more than a decade since San Francisco has hosted our Annual Meeting and Scientific Symposium, and we're excited to be back.

We have many new features this year, including a Clinical Skills Building track, Satellite CME Symposium, and our highly anticipated debate on psychedelics: Promises and Perils of Psychedelics in Addiction Treatment.

We all know that one of the best parts of attending the Annual Meeting are the special events that help us all unwind and allow us to network and meet new colleagues. Get ready for some Golden Era Glamour as we celebrate the iconic style of the 1950s during our closing reception Saturday. Don't miss our Mentorship Mingle Thursday night.

I hope everyone takes advantage of this opportunity to expand your knowledge of Addiction Psychiatry and network with colleagues. AAAP is a place where national leaders in Addiction Psychiatry are accessible and eager to meet attendees and provide opportunities to learn from one another. I look forward to seeing all of you and am sure we will have a productive and enjoyable meeting!



John J. Mariani, MD  
AAAP President

# What is AAAP?

AAAP is a professional membership organization founded in 1985 with more than 2,000 members. Membership includes Addiction Psychiatrists, general psychiatrists, primary care providers, nurses, pharmacists and those in training contributing to the field of substance use disorders and mental disorders. Becoming a AAAP member includes:



Free Educational activities



AAAP Member Mentoring Program



Networking events and programs



AAAP News, email bulletins and member-only content



Online subscription to  
*The American Journal on Addictions*



Member-only discounts to AAAP Annual Meeting and other on demand courses.


As one of the most informative addiction conferences in the country, our annual meeting provides the latest scientific and clinical approaches in substance use and psychiatric disorders.

## Get ready to:

- Learn the latest evidence-based information in Addiction Psychiatry through a wide variety of workshops and symposia.
- Meet the leading experts in the field of Addiction Psychiatry.
- Meet new friends and re-connect with colleagues.
- Learn while having fun!







# Outstanding Achievement and Service Award

---

## Andrew Saxon, MD

Preceding his entry into psychiatry, Dr. Saxon completed an internal medicine internship and worked for 4 years as an emergency room physician.

Subsequent to his general psychiatry residency at the University of Washington, Dr. Saxon has more than four decades of experience as a clinical and research Addiction Psychiatrist. Dr. Saxon is board certified with added qualifications in Addiction Psychiatry by the American Board of Psychiatry and Neurology. Dr. Saxon sits on the editorial boards of the journals, *Drug and Alcohol Dependence* and *General Hospital Psychiatry* and is section editor for substance use disorders for UpToDate. He is a lifetime Distinguished Fellow of the American Psychiatric Association, where he served from 2017-2019 as that organization's Chair of the Council on Addiction Psychiatry, and a Fellow of the American Society of Addiction Medicine, as well as a member of College on Problems of Drug Dependence and of American Academy of Addiction Psychiatry.

Dr. Saxon's current research work is supported by the VA and the National Institute on Drug Abuse and involves pharmacotherapies and psychotherapies for alcohol, tobacco, and opioid use disorders, work in co-occurrence of substance use disorders and posttraumatic stress disorder, phenomenology and epidemiology of cannabis use, and treatment of substance use in primary care. He has more than 200 papers published in peer reviewed journals and has done numerous conference presentations.

# Schedule-at-a-Glance

The following will be open during conference hours:

**Lactation Room:** Intersect

**Speaker Practice:** Terrace Room

**Kids Corner** - Intersect Lounge

**Charging Stations:** Loggia, Gold

WiFi Code: AAAP25

# Schedule-at-a-Glance

## Wednesday, November 5

2:00 PM	9:00 PM	Check-in and Register	Grand Ballroom Foyer
2:00 PM	9:00 PM	Early Exhibitor Set-Up	Gold Room
4:00 PM	6:30 PM	Poster Presenter Set-up	Grand Ballroom, Foyer, Lounge
4:30 PM	5:30 PM	Area Directors Meeting	Oval Room
5:30 PM	6:30 PM	Opioid Response Network Veterans' Networking Event	Green Room

## Thursday, November 6

7:00 AM	9:00 am	Exhibitors set up	Gold Room
8:30 AM	9:00 AM	Welcome Remarks and AAAP State of the Association	Grand Ballroom
9:00 AM	5:00 PM	Exhibit Hall	Gold Room
9:00 AM	11:00 AM	<b>Symposium I</b> - Sex, Gambling and Social Media: Update on Treatment and Research of Behavioral Addictions	Grand Ballroom
10:00 AM	10:30 AM	Caregiver Meet-Up	Lobby
11:00 AM	12:00 PM	Medical Update	Grand Ballroom
12:00 PM	1:15 PM	Lunch and Member Committee Meetings	Refer to App
1:30 PM	3:30 PM	<b>Symposium II</b> - Treating Beyond the City Limits: Building Capacity in All Communities	Grand Ballroom
3:45 PM	5:15 PM	Concurrent Workshop Sessions A (1-5)	Refer to App
5:30 PM	6:30 PM	Welcome Reception and President's Address	Crown Room
6:30 PM	7:30 PM	Mentorship Event	French Room
7:30 PM	8:30 PM	<i>The AJA</i> Editorial Board Meeting Closed Meeting	Crystal Room
9:00 PM	10:00 PM	Recovery Meeting	Oval Room

## Friday, November 7

Starts	Ends	Function	Location
6:00 AM	7:00 AM	Wellness Activity	Lobby
7:00 AM	8:00 AM	Coffee, Tea	Gold Room
7:00 AM	4:00 PM	Exhibit Hall Open	Gold Room
7:00 AM	4:00 PM	Registration Open	Grand Ballroom Foyer
7:45 AM	8:00 AM	Welcome Remarks	Grand Ballroom
8:00 AM	9:00 AM	Outstanding Service and Achievement Award Fireside Chat: Andrew Saxon, MD	Grand Ballroom
9:00 AM	11:00 AM	<b>Symposium III</b> - Breaking Ground: A Legacy of Gender-Specific Addiction Research in the NIDA Clinical Trials Network	Grand Ballroom
11:00 AM	12:30 PM	Case Conference: A Hidden Diagnosis: Prenatal Alcohol Exposure and the Lifelong Psychiatric Sequelae of FASDs	Grand Ballroom
12:30 PM	1:45 PM	Lunch and Committee Meetings	Refer to App
2:00 PM	3:30 PM	Concurrent Workshop Sessions B (1-5)	Refer to App
3:45 PM	5:15 PM	Concurrent Paper Sessions 1, 2, 3	Refer to App
5:30 PM	7:00 PM	Film and Media Workshop	Grand Ballroom
7:00 PM	8:00 PM	Fellowship Forum	Crown Room
8:00 PM	9:00 PM	Addiction Psychiatry Fellowship Program Directors Meeting	French Room
8:30 PM		Trainee Mingle in Social Area	Meet in lobby
9:00 PM	10:00 PM	Recovery Meeting	Oval Room



## Saturday, November 8

Starts	Ends	Function	Location
7:00 AM	12:30 PM	Exhibit Hall	Gold Room
7:00 AM	8:15 AM	Breakfast Courtesy of Eli Lilly – Satellite CME by Medscape	Terrace Room
7:00 AM	8:15 AM	Satellite CME Symposium: Shining a Light on Alcohol Use Disorder Through the Eyes of the Patient: Improving Recognition and Management	Terrace Room
7:30 AM	4:00 PM	Registration Open	Grand Ballroom Foyer
8:30 AM	10:30 AM	<b>Symposium IV</b> - From Trends to Treatment: Advancing Care for Perinatal Substance Use Disorders	Grand Ballroom
10:30 AM	12:00 PM	<b>Debate</b> - The High-Stakes Debate: Promises and Perils of Psychedelics in Addiction Treatment	Grand Ballroom
12:00 PM	2:00 PM	Lunch on Key Topics	Gold Room
2:00 PM	4:00 PM	Exhibitor Breakdown	Gold Room
2:00 PM	3:30 PM	Addiction Psychiatry Annual Review: 2025 Highest Impact Publications	Grand Ballroom
3:45 PM	5:15 PM	Concurrent Workshop Sessions C (1-5)	Refer to App
5:15 PM	6:15 PM	Area Meetings	Refer to App
6:30 PM	7:30 PM	Recognition and Award Ceremony	Grand Ballroom
7:30 PM	8:30 PM	Closing Reception	Grand Ballroom
9:00 PM	10:00 PM	Recovery Meeting	Oval Room

## Sunday, November 9

Starts	Ends	Function	Location
7:00 AM	8:00 AM	Light Breakfast and Networking	Grand Ballroom Foyer
7:30 AM	8:30 AM	SPC Meeting	French Room
8:00 AM	9:30 AM	Poster Walk and Non-CME Posters	Grand Ballroom, Foyer, Lounge
9:30 AM	10:30 PM	<b>Mini-Symposium</b> - Changing the Landscape: SAMHSA's 2024 Rule and the Future of Opioid Treatment	Grand Ballroom

# Accreditation and Designation Statements

---

## Accreditation Statement



In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## Target Audience Statement

This activity was designed for physicians and other healthcare professionals and is designated for learners in the following ways:

## Physician Designation Statement

American Academy of Addiction Psychiatry designates this live activity for a maximum of 24.5 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## Other Health Professionals Designation Statement

Participants will receive a Certificate of Attendance stating this program is designated for 24.5 *AMA PRA Category 1 Credits*<sup>™</sup>. This credit is accepted by the AANP and the AAPA.

# Symposium I

---

## Sex, Gambling and Social Media: Update on Treatment and Research of Behavioral Addictions

**THURSDAY, NOVEMBER 6 | 9:00 AM - 11:00 AM**

---

Behavioral addictions remain an under-appreciated concept in addiction medicine, generally given short shrift in the literature, yet commonly encountered by addiction psychiatrists. We will present research and assessment scales and provide practical tools for the clinician encountering patients with gambling, social media and sexual behaviors that rise to the level of addictions. Each presenter will start by addressing the diagnostic issues – whether under the category of impulse disorders, compulsions or addictions – and delve into common comorbid conditions. Next, each presenter will outline the psychotherapeutic, self-help and pharmacologic treatments. Finally, each presenter will present a case example from their own clinical experience. There will be a short questions-and-answer session after each presenter with a more substantive audience discussion at the end.



### KENNETH ROSENBERG, MD

#### *Chairperson and Presenter*

Weill Cornell Medical College, Co-editor of Behavioral Addictions (Elsevier), author of Infidelity (Hachette) and Bedlam (Penguin Random House) and director of films for PBS and HBO to for which he is the recipient of a Oscar shortlist, George Foster Peabody, duPont Columbia and AAAP Arts and Advocacy awards.



### LISA GOLDFARB, MD

#### *Co-Chairperson and Presenter*

Dr. Lisa Goldfarb is Board-Certified in both Psychiatry and Addiction Psychiatry. A graduate of the Massachusetts Institute of Technology and the Columbia University College of Physicians and Surgeons, Dr. Goldfarb is an Assistant Clinical Professor of Psychiatry at NYU Langone School of Medicine and a lecturer at the Columbia University Center for Psychoanalytic Training and Research.





## TIM FONG, MD

### *Presenter*

Dr. Fong is a Professor of Psychiatry at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA. He is board certified in adult and addiction psychiatry. He is the co-director of the UCLA Gambling Studies Program. The purpose of this program is to examine the clinical characteristics of gambling disorder in order to develop effective, evidence-based prevention and treatment strategies. Dr. Fong is also a member of the Steering Committee of the UCLA Center for Cannabis and Cannabinoids whose mission is to address the most pressing questions related to the impact of cannabis legalization through rigorous scientific study and discourse across disciplines. Currently, he is the President-Elect of AAAP and has been a member of AAAP since 1997.



## JON GRANT, MD

### *Presenter*

Jon E. Grant is a Professor of Psychiatry & Behavioral Neuroscience at the University of Chicago where he directs a clinic and research lab on addictive, compulsive and impulsive disorders. Professor Grant is the author of over 500 peer-reviewed scientific articles, 15 books, and his research has been supported by NIMH and NIDA.

# Symposium II

---

## Treating Beyond the City Limits: Building Capacity in All Communities

**THURSDAY, NOVEMBER 6 | 1:30 PM - 3:30 PM**

Rural communities have specific challenges that have led to poorer health outcomes and shorter life expectancies compared to non-rural settings. These communities have been overrepresented in the so-called “Deaths of Despair” – deaths due to drug overdose, suicide, and liver disease. Substance use and SUD are the main drivers of these deaths. Tragically, although SUD is entirely treatable, access to providers in rural communities qualified and comfortable in addressing SUD remains a limiting factor in supplying lifesaving care. Novel models of care delivery as well as innovative training programs to expand the SUD workforce are essential to meet the unique needs of rural communities.

West Virginia, the only state entirely within rural Appalachia, has been the epicenter of our nation’s addiction epidemic and remains the number one outlier among states in the overdose death rate. West Virginia has challenges common to other rural regions, such as transportation and economic limitations, as well as political realities unique to West Virginia, such as extremely tight regulations restricting MOUD. The experience of navigating these challenges through an academic medical center will be described with the intent of sharing lessons learned and building capacity that could be successfully applied to rural and other populations with limited resources. Specific focus will be on clinical application, development of research, and building educational programs.



**JAMES BERRY, DO**

*Chairperson*

Addiction Psychiatrist and Chair of Behavioral Medicine and Psychiatry at West Virginia University School of Medicine's Rockefeller Neuroscience Institute.



**DANIEL ELSWICK, MD**

*Presenter*

Dr. Daniel E. Elswick is a Professor and holds the Dana L. and Peggy M. Farnsworth Endowed Chair of Educational Psychiatry in the Department of Behavioral Medicine and Psychiatry at West Virginia University (WVU). He also serves as the Vice Chair for Education and Residency Director for his department. In 2023, Dr. Elswick was appointed Assistant Dean for Academic Initiatives at the WVU School of Medicine's Eastern Campus. A recognized national leader in the development of graduate medical education programs for rural and underserved populations, Dr. Elswick is deeply committed to addressing health disparities through the expansion of the medical workforce.



## WANHONG ZHENG, MD

### *Presenter*

Dr. Wanhong Zheng is a Professor and Vice Chair of Research in the Department of Behavioral Medicine and Psychiatry at West Virginia University (WVU). He also serves as the Director of the WVU Addiction Medicine Fellowship Program and the Director of Inpatient Services at the Chestnut Ridge Center. As the Principal Investigator for the 2020-2025 HRSA Addiction Fellowship Expansion Grant at WVU, Dr. Zheng played an important role in advancing addiction medicine training. Under his leadership, WVU established a Comprehensive Training Track (CTT) focused on serving rural populations and leveraging telemedicine to expand access to care.



## KARI LAW, MD

### *Presenter*

Dr. Law has a compelling clinical and administrative background with a focus on telemedicine and its utilization for rural psychiatric needs. She is a Professor within the West Virginia University Rockefeller Neuroscience Institute Department of Behavioral Medicine & Psychiatry where she serves as the Telepsychiatry Program director and Vice Chair for Clinical Operations. She is currently serving as the Chief of Staff for WVU Hospitals medical staff. She has been awarded multiple HRSA telehealth grants as PI or co-PI since 2012. Each of these grants focused on the implementation of and/or expansion of evidence-based services for telepsychiatry in rural West Virginia which have included access to addiction treatment, school based services, telepsychiatry ED consultation and expansion of rural training opportunities in psychiatry and addiction psychiatry. Dr. Law is board-certified in child and adolescent psychiatry, adult psychiatry and forensic psychiatry.

# Symposium III

---

## Breaking Ground: A Legacy of Gender-Specific Addiction Research in the NIDA Clinical Trials Network

**FRIDAY, NOVEMBER 7, | 9:00 AM - 11:00 AM**

Despite rising rates of substance use disorders (SUD) in women and the narrowing of the SUD gender prevalence ratio in the United States, large knowledge gaps in gender-specific treatment remain. Since 2001, the NIDA Clinical Trials Network (CTN) Gender Special Interest Group (GSIG) has provided opportunities to bring a gender lens to national multi-site clinical trials, ancillary studies, secondary data analyses, recommendations for data collection and demographic data, among other contributions to CTN and the SUD treatment field. The GSIG further contributes to the national dialogue on SUD treatment for women (including adolescent girls and transgender women) and other gender diverse people, historically underrepresented in and excluded from research trials, by developing study concepts, conducting secondary data analyses and critical reviews, and raising awareness of challenges to accomplishing rigorous scientific research that will benefit women.

This symposium will provide background on gender differences and the knowledge gap, an overview of the purpose of the CTN GSIG and highlight more than two decades of accomplishments, followed by summaries of three studies highlighting gender-specific research in the CTN. The symposium will close with future directions and recommendations for research including, improving the inclusion of intersectional identities in recruitment reach and analyses, reproductive health, pregnant and parenting people, and methodological considerations for clinical trials to enhance capacity to collect and understand data related to gender.





## **SHELLY GREENFIELD, MD, MPH**

### *Chairperson and Presenter*

Shelly F. Greenfield, MD, MPH is Professor of Psychiatry at Harvard Medical School and the Kristine M. Trustey Endowed Chair of Psychiatry at McLean Hospital where she also serves as the Chief Academic Officer. She is the Chief of the Division of Women's Mental Health and the Director of Clinical and Health Services Research and Education in the Alcohol, Drug and Addiction Treatment Program at McLean Hospital. Dr. Greenfield is an addiction psychiatrist, clinician and researcher. She was a Radcliffe Fellow at the Harvard Radcliffe Institute 2024-2025 where she focused her research on women and substance use disorders. She has been Principal Investigator and Co-Investigator on federally funded research with studies on treatment for substance use disorders, gender differences in substance disorders, and health services for substance disorders. She received a National Institute on Drug Abuse (NIDA)-funded career award in substance use disorder patient-oriented research (2005-2016). Funded by grants from NIH/NIDA, she developed and tested a new manual-based group therapy for women with substance use disorders, the Women's Recovery Group (WRG). The WRG is an evidence-based treatment and the manual for dissemination was published in 2016, *Treating Women with Substance Use Disorders: The Women's Recovery Group Manual*. She is Past President of the American Academy of Addiction Psychiatry and past chair of the American Psychiatric Association's Council on Addiction Psychiatry. She was the Editor-in-Chief of the *Harvard Review of Psychiatry*, a position she held for 16 years (2002-2018). Dr. Greenfield has served as co-chair of the NIDA Clinical Trials Network Gender Special Interest Group for more than two decades. She was a member of the Advisory Committee on Services for Women for the U.S. Substance Abuse and Mental Health Services Administration (2011-2017) and a member of the NIH National Advisory Council on Drug Abuse (2021-2024). She has been elected to the American College of Psychiatrists and the College on Problems of Drug Dependence and is a Distinguished Fellow of the American Psychiatric Association. She received the R. Brinkley Smithers Distinguished Scientist Award from the American Society of Addiction Medicine and the A. Clifford Barger Award for Excellence in Mentoring from Harvard Medical School.



### AIMEE CAMPBELL, PHD

#### *Presenter*

Aimee Campbell, PhD is a Professor of Clinical Psychiatric Social Work in the Department of Psychiatry at Columbia University Irving Medical Center and a Research Scientist in the Division on Substance Use Disorders at the New York State Psychiatric Institute. Her research focuses on the development and testing of individual and program level interventions for substance use disorders and co-occurring health and mental health challenges with the objective of increasing adoption and implementation of best practice treatments. Dr. Campbell has been involved in addiction treatment and implementation research, primarily in community settings and in partnership with community providers and consumers, for over 20 years, including trials focused on women's treatment needs and culturally responsive services with Tribal and Indigenous communities. She received her master's degree and doctorate from Columbia University School of Social Work.



## DENISE HIEN, PHD, ABPP

### *Presenter*

Denise Hien, PhD, ABPP, is Senior Vice Provost of Research, Distinguished Professor and Helen E. Chaney Endowed Chair in Alcohol Studies of the Center of Alcohol & Substance Use Studies, Graduate School of Applied and Professional Psychology at Rutgers University-New Brunswick in New Jersey. Considered a leader in the field, with continuous funding from the National Institute on Drug Abuse and National Institute on Alcoholism and Alcohol Abuse for over 30 years, her body of work has contributed to the evidence base on the treatment of individuals with trauma-related psychiatric disorders and their comorbidity with addictions, through conducting single- and multi-site clinical trials across the United States in community-based substance abuse treatment settings. Most of her NIH-funded research has focused on understanding and treating traumatic stress and PTSD among women and underrepresented minoritized populations (primarily Black/African American and Latinx women in Harlem, NY) with key goals of addressing health inequalities and understanding the ways in which race/ethnicity, culture, gender, and other aspects of social identities influence the treatment utilization and outcomes. She is board-certified in clinical psychology and serves on numerous national boards and scientific advisory groups, particularly those supporting diversity training and mentoring for underrepresented groups in the sciences. Among many honors for her scholarship and mentoring, in 2023 she was given the Inaugural Mary Jean Kreek Award for Underserved Populations from the College of Problems of Drug Dependence and the Award for Excellence in Trauma Services for the Underserved: Policy, Advocacy from the International Society for Traumatic Stress Studies.



### **MICHELLE LOFWALL, MD**

#### *Presenter*

Dr. Michelle Lofwall, board-certified in psychiatry and addiction medicine, is a Professor in the Departments of Behavioral Science and Psychiatry and the Bell Alcohol and Addictions Endowed Chair at the University of Kentucky (UK). She received her bachelors degree from Northwestern University in Psychology and her MD and Masters in Pathology from Chicago Medical School. She completed internship, psychiatry residency, and a fellowship in behavioral pharmacology from Johns Hopkins University. Currently, she is the medical director of UK's Robert Straus and First Bridge Clinics, which provide comprehensive opioid use disorder (OUD) treatment within the UK Center on Drug and Alcohol Research. Her passion is in improving the care of patients with addiction, and her research has included evaluation of novel treatments for opioid use disorder (e.g., buprenorphine implants and depot injections), physician training, understanding factors associated with buprenorphine diversion, and improving care of complex patients with OUD and other medical/psychiatric comorbidities. She was elected as a Distinguished Fellow of American Society of Addiction Medicine (ASAM) and the American Psychiatric Association, is a past ASAM board member and co-director of the American Academy of Addiction Psychiatry's annual addiction treatment review course. She has received numerous teaching and mentoring awards and was an expert panel member for SAMHSA's Treatment Improvement Protocol on Medication Treatment for Opioid Use Disorder and invited speaker to the National Academy of Medicine.

# Symposium III

## Presenters



### CHRISTI PATTEN, PHD, MA, LP

#### *Presenter*

Christi Patten, PhD, MA, LP, is a licensed Clinical Psychologist, Professor of Psychology, and Director of the Behavioral Health Research Program within the Department of Psychiatry and Psychology at Mayo Clinic Rochester, MN. She directs the Rural Health Core within the Mayo Clinic NIH-funded Center for Clinical and Translational Science (CCaTS). Dr. Patten's research team focuses on community-based participatory research to develop culturally aligned interventions for smoking cessation and other health promotion interventions among Indigenous communities. Through community engagement, her research team has developed novel digital health access strategies to improve the reach of evidence-based interventions among Indigenous and rural populations. Dr. Patten's current project, funded by the NIDA CTN NorthStar Node, focuses on developing and piloting a Facebook group intervention for supporting opioid recovery among Indigenous women in Minnesota. Dr. Patten served as recent co-chair of the Health Equity Network for the Society of Research on Nicotine and Tobacco and has held many other leadership roles nationally.



### DAWN SUGARMAN, PHD

#### *Presenter*

Dawn E. Sugarman, PhD, is a research psychologist in the Division of Alcohol, Drugs, and Addiction at McLean Hospital and an Assistant Professor in the Department of Psychiatry at Harvard Medical School. She is the Director of McLean Hospital's Clinical Measurement Initiative, focused on electronic collection of patient-reported outcomes to inform individual routine patient care and assist in program outcomes assessment. Dr. Sugarman focuses her research and clinical work on the treatment of addictive behaviors. She is particularly interested in gender-specific treatment for substance use disorders and the use of technology in effective treatment dissemination. Dr. Sugarman was the inaugural recipient of the Sarles Young Investigator Award for Research on Women and Addiction. She is a current recipient of a National Institute on Drug Abuse (NIDA)-funded career development award focused on increasing women's engagement in medication treatment for opioid use disorder through digital intervention. Dr. Sugarman also serves as the Managing Editor for the Harvard Review of Psychiatry.





### **MARGARET PASCHEN-WOLFF, DRPH**

#### *Presenter*

Dr. Margaret Paschen-Wolff is an Assistant Professor of Clinical Psychiatric Social Work in the Department of Psychiatry at the Columbia University Irving Medical Center, and a Research Scientist at the New York State Psychiatric Institute. Dr. Paschen-Wolff's academic background includes a Master of Science in Social Work and a Doctorate in Public Health. For nearly twenty years, Dr. Paschen-Wolff has managed and directed various federally funded projects in diverse environments, from academic research settings to real-world public health clinics. Dr. Paschen-Wolff is a Project Director/Co-Investigator for two National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) studies focused on improving services for HIV and substance use in health care settings across the U.S. She is part of the Opioid Response Network (ORN), a SAMHSA-funded initiative to expand capacity to provide technical assistance in evidence-based practices to meet locally identified needs for prevention, treatment, recovery, and harm reduction related to opioid and stimulant use disorders. Broadly, Dr. Paschen-Wolff's research has focused on supporting optimal health outcomes among LGBTQ+ people, as well as people living with HIV and substance use disorders, and facilitating the implementation of effective substance use disorder treatment and other services in health care settings.

# Symposium IV

---

## From Trends to Treatment: Advancing Care for Perinatal Substance Use Disorders

**SATURDAY, NOVEMBER 8, | 8:30 AM - 10:30 AM**

In the United States, drug overdose and suicide combine to constitute the leading cause of maternal mortality, with over 80% of these deaths determined to be preventable. Pregnant and postpartum people are often excluded from substance use disorders (SUDs) research, leaving gaps in our understanding of how best to address SUDs during this critical period. Additionally, traditional models of care are likely insufficient in screening and treating pregnant and postpartum people who use substances. The overall goals of this symposium are to: 1) discuss the literature for research and treatment of pregnant and postpartum individuals with SUD and how to apply the extant research to guide clinical decisions for the treatment of perinatal SUDs and common comorbid mental health disorders; and 2) highlight novel and/or complimentary approaches to treating and caring for this population. We will discuss the evidence base for the use of medications for the treatment of perinatal substance use disorders and comorbid conditions, and considerations for prescribing these medications during pregnancy and lactation. This symposium will highlight ways to deliver patient-centered care and bridge the gap between addiction psychiatry and other disciplines using innovative methods

# Symposium IV

---



## MARIE HAYES, PHD

### *Chairperson and Presenter*

Marie Hayes is a Clinical Psychologist and Assistant Professor in the Department of Psychiatry and Behavioral Sciences at MUSC. She received her PhD in Clinical Health Psychology from UNC Charlotte and completed a predoctoral internship at Duke University Medical Center. Dr. Hayes completed a postdoctoral fellowship at the Levine Cancer Institute. She is involved in clinical research, supervision and patient care roles. Her professional interests are globally centered around health psychology and include reproductive behavioral health, perinatal substance use and the role of stress and sleep in promoting wellness.



## CONSTANCE GUILLE, MD

### *Presenter*

Connie Guille, MD is a Professor in the Departments of Psychiatry and Behavioral Sciences and Obstetrics and Gynecology and is the Director of the Women's Reproductive Behavioral Health Division at the Medical University of South Carolina (MUSC). She completed her Psychiatry Residency training and subspecialty training in Reproductive Psychiatry at Yale University. The focus of her clinical and clinical research is in the integration of mental health and addiction treatment in women's health, specifically for the treatment of substance use disorders among pregnant and postpartum women. Since 2011 Dr. Guille has been federally and privately funded to conduct clinical research focused on the development, and evaluation of patient and provider-informed, technology enhanced, novel treatments for Perinatal Mental Health and Substance Use Disorders. She receives funding from the National Institute of Health, Patient-Centered Outcomes Research Institute, and private foundations such as the Duke Endowment to develop treatments to improve women's health.



## **SARA WITCRAFT, PHD**

### *Presenter*

Dr. Sara Witcraft is an Assistant Professor and Licensed Clinical Psychologist in the Women's Reproductive Behavioral Health (WRBH) Division at the Medical University of South Carolina. Her research focuses on addressing transdiagnostic psychological mechanisms and utilizing innovative digital solutions to improve quality, access, and equity of evidence-based behavioral and pharmacological treatments for individuals with substance use disorders and co-occurring mental health conditions.



## **RUBIN AUJLA, MD**

### *Presenter*

After completing her Masters in Public Health at Tulane University, Rubin Aujla attended the University of South Carolina for medical school. She then returned to Tulane for her psychiatry residency, including a year as chief resident. Dr Aujla completed her perinatal psychiatry fellowship at the Medical University of South Carolina where she now works as a perinatal psychiatrist and the Clinic Director for the Women's Reproductive Behavioral Health Clinic.



## **COURTNEY KING, PHD**

### *Presenter*

Dr. Courtney King is an Assistant Professor in the Department of Psychiatry and Behavioral Sciences, and Associate Director of Research for the Women's Reproductive Behavioral Health Division at the Medical University of South Carolina.

# Mini Symposium

---

## Changing the Landscape: SAMHSA's 2024 Rule and the Future of Opioid Treatment

**SUNDAY, NOVEMBER 9, | 9:30 AM - 10:30 AM**

The opioid epidemic continues to devastate communities, with overdoses from fentanyl and other illicit opioids contributing to a rising death toll. Medications for Opioid Use Disorder (MOUD), including methadone, have been proven to reduce overdose deaths by over 50%. Methadone has been used for MOUD for over 50 years, and over that time has been regulated by the federal government, remaining restricted to specialized treatment programs. There are currently over 2,000 Opioid Treatment Programs (OTPs) in the US; however, there are still many people who need treatment and have difficulty accessing it.

In April 2024, the Substance Abuse and Mental Health Services Administration (SAMHSA) introduced significant regulatory updates, the first substantial change to OTP regulations since the 1970s. The new Final Rule alters key aspects of methadone administration, including initial dosing guidelines, take-home medication policies, interpretation of ongoing substance use, and the integration of telemedicine. These changes are substantial, and determining how to implement them in a complex system involving medical providers, nurses, counselors, peers, and other clinic staff is challenging.

This session will explore the challenges and outcomes associated with implementing the Final Rule across 60 OTPs in 12 states. Since some states have allowed the Final Rule changes to proceed and others have limited implementation by state regulations, a “natural experiment” allows a comparison of states that have adopted the new policies with those that have not, offering insight into operational issues, clinical impact, and patient outcomes.





## HILLARY TAMAR, MD

### *Chairperson*

Dr. Hillary Tamar is the Medical Director of Community Medical Services' Eastern Territory, overseeing Wisconsin, Minnesota, Michigan, Ohio, Oregon, Indiana, and Texas. Dr. Tamar completed her undergraduate studies at Marquette University, and her medical education at Chicago Medical School. She trained in Family Medicine at the University of Arizona-Phoenix, and then went on to complete a fellowship program in Addiction Medicine at Swedish Medical Center, in Seattle, WA. Her special interests within Addiction Medicine include federal and state opioid treatment program regulation, pregnant patients with substance use disorders, and harm reduction.



## FRAZER GRANT, MD

### *Presenter*

Dr. Frazer Grant is the Medical Director of the Colorado Region for Community Medical Services. Dr. Grant completed his undergraduate studies at Emory University, and his medical education at University of Missouri Medical School. He trained in Emergency Medicine at the University of Tennessee Health Science Center and then went on to complete a fellowship program in Addiction Medicine. His special interests within Addiction Medicine include Medication Assisted Treatment in correctional settings, Opiate Treatment Programs, and harm reduction.

# Debate

---

## The High-Stakes Debate: Promises and Perils of Psychedelics in Addiction Treatment

**SATURDAY, NOVEMBER 8 | 10:30 AM : 12:00 PM**

This debate will explore the therapeutic potential of psychedelics in treating substance use disorders (SUD), a topic that has sparked significant interest and polarized opinions within the medical community. Leading experts will examine both the promises and perils of psychedelic-assisted therapy, discussing clinical trial results, safety concerns, regulatory challenges, and the risk of misuse. The session will feature structured presentations and rebuttals to critically assess the efficacy, safety, and scalability of psychedelic treatments for SUD. By presenting evidence-based perspectives, this debate aims to inform clinicians, researchers, and policymakers about the potential and limitations of integrating psychedelics into mainstream addiction treatment practices.

# Debate

---



## JOAO DE AQUINO, MD

### *Chairperson and Presenter*

Dr. De Aquino is an Assistant Professor of Psychiatry at the Yale University School of Medicine. In addition to treating persons with substance use disorders and co-occurring medical and psychiatric disorders, he uses behavioral pharmacology, computerized assessment of pain, and clinical trial approaches to develop novel therapeutics for persons living with chronic pain and addiction.



## PETER HENDRICKS, PHD

### *Presenter*

Dr. Hendricks is a clinical psychologist and Heersink Endowed Chair of Psychiatry in the Department of Psychiatry and Behavioral Neurobiology at UAB. His research centers on the development of novel and potentially more effective treatments for substance use disorders and comorbid conditions, with specific areas of focus on vulnerable populations, including individuals in the criminal justice system. He is currently Principal Investigator of pilot trials of psilocybin-facilitated psychotherapy in the treatment of fibromyalgia, and low doses or “microdoses” of psilocybin in the treatment of demoralization. Dr. Hendricks is site PI of a NIDA-funded study of psilocybin for smoking cessation and co-editor-in-chief of *Psychedelic Medicine*.



## STEPHEN ROSS, MD

### *Presenter*

Dr. Stephen Ross is Professor of Psychiatry and Child & Adolescent Psychiatry at the NYU Grossman School of Medicine. Dr. Ross is a founding member of the NYU Psychedelic Research Group and is currently Associate Director of the NYU Langone Health (NYULH) Center for Psychedelic Medicine and Director of the NYULH Psychedelic Medicine Research Training Program. Dr Ross has been involved in a variety of leadership roles in administration, teaching and research. He previously served as Director of the Division of Alcoholism and Drug Abuse in the Psychiatry Department at Bellevue Hospital Center for 12 years, Director of Addiction Psychiatry at NYULH/Tisch Hospital, Director of the NYU Addiction Psychiatry Fellowship, Director of the Bellevue Inpatient Dual Diagnosis Training Unit, and Director of the Bellevue Opioid Overdose Prevention Program. Dr Ross's main research interests focus on developing novel pharmacologic-psychosocial approaches to treating: addictive disorders, including the intersection between pain and addiction; psychiatric and existential distress associated with advanced or terminal cancer; major depression; PTSD; and personality disorders. Dr Ross is principal investigator or co-principal investigator on several ongoing and completed psychedelic-focused studies at NYULH including: phase II RCT of psilocybin-assisted psychotherapy in patients with life-threatening cancer-related psychiatric and existential distress, phase I/II RCT of LSD-assisted psychotherapy in advanced cancer pain syndromes, phase II RCT of psilocybin-assisted psychotherapy in alcohol use disorder, phase I/II controlled trial administering psilocybin to religious professionals, and phase II RCT of psilocybin treatment for Major Depressive Disorder. Dr Ross also acts as a co-investigator and study therapist for phase II/III trials of MDMA-assisted psychotherapy for PTSD, and is an expert in cannabinoid therapeutics and PI of a NIDA funded study of CBD administration in patients with chronic radicular pain on chronic opioid therapy.

**ALBERT GARCIA-ROMEU, PHD***Discussant*

Albert Garcia-Romeu, Ph.D. is an Associate Professor of Psychiatry and Behavioral Sciences and the Susan Hill Ward Professor in Psychedelics and Consciousness at the Johns Hopkins University School of Medicine. His research examines the effects of psychedelics in humans, with a focus on psilocybin as an aid in the treatment of addiction. He earned his doctorate in psychology in 2012 from Sofia University in Palo Alto, CA where he studied self-transcendence, spiritual experiences, and their relationship to mental health. He completed a postdoctoral fellowship in behavioral pharmacology at Johns Hopkins where he trained in the conduct of clinical research with psychedelics, and subsequently joined the faculty. His current research interests include clinical applications of psychedelics, real-world drug use patterns, diversity in science, and the role of spirituality in wellbeing. He is a founding member and Associate Director of the Johns Hopkins Center for Psychedelic and Consciousness Research and a founding member of the International Society for Research on Psychedelics. He is an Associate Editor for the journal *Psychedelic Medicine*.

**DEEPAK CYRIL D'SOUZA, MD***Discussant*

Vikram Sodhi Professor of Psychiatry, Yale University School of Medicine. Decades of experience conducting human psychopharmacological studies with THC, ketamine, amphetamine etc. Interest in the overlap of cannabis, cannabinoids and mental illness.



## **BERTHA MADRAS, PHD**

### *Discussant*

Bertha Madras is a Professor of Psychobiology at Harvard Medical School (at Harvard nearly 38 years), based at McLean Hospital and cross-appointed at Massachusetts General Hospital. Scientific Research. Her research has focused on neurobiology, pharmacology, brain imaging, drug discovery for addiction, neuropsychiatric disorders, and drug policy. With collaborators, her lab discovered: (1) methods for detecting Parkinson's disease in living brain; (2) molecular targets in brain of cocaine, ecstasy (MDMA), modafinil, THC (of marijuana), CBD; (3) different responses of psychoactive drugs in adolescents/adults; (4) new candidate therapeutics; (5) THC toxicity, others.



## **CHRISTOPHER PITTENGER, MD, PHD**

### *Discussant*

Christopher Pittenger, MD, Ph.D. is Mears & Jameson Professor of Psychiatry and Deputy Chair for Translational Research in the Department of Psychiatry, Professor of Psychology, Neuroscience, and in the Child Study Center, and Director of the Center for Brain and Mind Health, the Clinical Neuroscience Research Unit, and the Center for Psychedelic Science at Yale University.



# Addiction Psychiatry

## Annual Review

---

### 2025 Highest Impact Publications

**SATURDAY, NOVEMBER 8 | 2:00 PM - 3:30 PM**

This presentation seeks to provide an annual review of the highest impact peer-reviewed publications and newsmaker events across the field of Addiction Psychiatry from 2024. The goal of this session is to provide concise, critical summaries of the most important peer-reviewed publications and newsmaker events of the past year, organized using key topic areas such as addiction neurobiology, epidemiology, pharmacology, intoxication and withdrawal syndromes, screening and diagnosis, mutual help, harm reduction, dual diagnoses, and pharmacologic and behavioral interventions. We will provide more in-depth focus on a small, select group of articles that are high impact and likely to fundamentally change clinical practice.

The Chairs and Presenters will survey the most prominent medical, psychiatric, and addiction journals as well as newsletters to select and rank recent articles by publication metrics (Journal Impact Factor, Most Downloaded and Most Viewed, and Altmetric scores), expert opinion, and topic focus. Articles will cover key events and topics in Addiction Psychiatry from 2024. The Panel of Discussants is comprised of senior AAAP leaders and experts to provide commentary on the articles and engage in audience questions and discussion.

# Addiction Psychiatry Annual Review

## Presenters



### CARLA MARIENFELD, MD

#### *Chairperson and Presenter*

Dr. Marienfeld is board-certified in psychiatry, addiction psychiatry, and addiction medicine, and she is a Clinical Professor at the University of California San Diego who supports recovery in an evidence based, harm-reduction approach through motivational interviewing and medication treatment. She was named a San Diego Top Doctor in 2021 as Medical Director for the UC San Diego Substance Treatment and Recovery (STAR) program. Her research involves populations with substance use disorders, including pregnant women and the development of their offspring, often using analysis of electronic medical record data. She has authored over three dozen peer reviewed articles, book chapters, practice guidelines, and invited commentaries, and she edited two books: *Motivational Interviewing for Clinical Practice* and *Absolute Addiction Psychiatry Review: An essential board exam study guide*. She has a record of grant funding for research and founding the UCSD Addiction Psychiatry Fellowship Program, where she serves as Program Director. She has been highly involved in the education of colleagues and trainees about addiction psychiatry, buprenorphine treatment, and motivational interviewing. Dr. Marienfeld completed a fellowship in addiction psychiatry and residency training in psychiatry at Yale. During her residency, she was chief resident of psychiatry and founded (and later led as junior faculty) the Yale Global Mental Health Program. She earned a medical degree with honors from Baylor College of Medicine in Houston. She is active in many professional organizations, including the American Society of Addiction Medicine, the American Association of Addiction Psychiatry, and the American Psychiatric Association.

# Addiction Psychiatry Annual Review

## Presenters



### **BRIAN HURLEY, MD, MBA, FAPA, DFASAM**

#### *Presenter*

Dr. Hurley is an addiction psychiatrist and the Medical Director of the Division of Substance Abuse Prevention and Control in the Los Angeles County Department of Public Health and a volunteer assistant clinical professor of addiction medicine in the UCLA Department of Family Medicine. He is the President of the American Society of Addiction Medicine and gives presentations around the world regarding addiction medicine and motivational interviewing. He is a Primary Investigator for an award to the Los Angeles County Department of Public Health from the Substance Abuse Mental Health Services Administration's first Harm Reduction Grant Program. Additionally, he is the grant lead for three Medications for Addiction Treatment Access Points projects funded by the Sierra Health Foundation supporting access to medications for addiction treatment across Los Angeles County. He is a member of the Motivational Interviewing Network of Trainers.



### **JOSHUA D. LEE, MD, MSC**

#### *Presenter*

Dr. Lee is a Professor in the Department of Population Health and Dept. Medicine/General Internal Medicine and Clinical Innovation at the NYU Grossman School of Medicine. He is Program Director of the NYU Addiction Medicine Fellowship and Co-Director of DPH's Section on Tobacco, Alcohol, and Drug Use. He is a clinician researcher focused on alcohol and opioid treatments in primary care and criminal justice populations and leads the NYUGSOM Hub of the NIDA Justice and Community Opioid Innovation Network. He is Science Advisor at Oar Health, an alcohol treatment provider

# Addiction Psychiatry Annual Review

## Discussant



### DARYL SHORTER, MD

#### *Discussant*

Dr. Daryl Shorter is a Diplomate of the American Board of Psychiatry and Neurology and is Board Certified in both General and Addiction Psychiatry. A graduate of Rice University (BA Sociology) and Baylor College of Medicine (MD), Dr. Shorter completed General Psychiatry residency at The Ohio State University Medical Center and Addiction Psychiatry fellowship at New York University/Langone Medical Center. Dr. Shorter is an Associate Professor in the Menninger Department of Psychiatry and Behavioral Sciences at Baylor College of Medicine. He also serves as the Medical Director of Addictions and Recovery Services at the Menninger Clinic as well as the Program Director of the BCM Addiction Psychiatry fellowship. Dr. Shorter is the author of numerous peer-reviewed publications and book chapters focusing on medication treatment of substance use disorders and addictions training in graduate medical education. In addition to his work at Menninger, Dr. Shorter is the psychiatrist of record at The Montrose Center, Houston's LGBTQ+ Behavioral Health and Community Center, where he supervises Addiction Psychiatry fellows who provide mental health and substance use disorder treatment services. He speaks widely on topics related to mental health, the LGBTQ+ community, and addictions treatment.

# Addiction Psychiatry Annual Review

Discussant



## LARISSA MOONEY, MD

### *Discussant*

Larissa Mooney, M.D. is a Professor of Clinical Psychiatry and Director of the Addiction Psychiatry Division in the Department of Psychiatry and Biobehavioral Sciences at UCLA. She is the Director of the UCLA-VA Addiction Psychiatry Fellowship Program and previously served as the Section Chief for Substance Use Disorders at the Greater Los Angeles VA. Dr. Mooney is the Immediate Past President of the American Academy of Addiction Psychiatry (AAAP), a Distinguished Fellow of the American Psychiatric Association (APA), and a Fellow of the American Society of Addiction Medicine (ASAM). She is one of two Principal Investigators for the Greater Southern California Node of the National Institute on Drug Abuse (NIDA) Clinical Trials Network.

# Medical Update

## Cardiovascular Risk Factors and Evaluation

THURSDAY, NOVEMBER 6 | 11:00 PM – 12:00 PM

This session will cover ASCVD guidelines and cardiac risk assessment; criteria for starting statins; hypertension treatment guidelines; how diabetes modifies prevention and treatment guidelines; how smoking nicotine/cannabis affects treatment thoughts; cocaine use; who should get a stress test and more.



**LYNETTE LISSIN, MD**

*Presenter*

Dr. Lissin is a clinical cardiologist at the large multi-specialty Palo Alto Medical Foundation in northern California. She earned her medical degree from Harvard Medical School and is Board Certified in Cardiology and Advanced Heart Failure as well as Echocardiography. She sees a wide range of ambulatory and hospitalized patients including adults with congenital heart disease and along the spectrum of congestive heart failure. Her clinic focuses on the prevention of coronary artery disease, hypertension, and genetic conditions, as well as those with cardio-oncology concerns. She enjoys incorporating aggressive lifestyle modification into risk reduction and disease management and frequently speaks to her large medical group and various communities about updates in cardiology.

# Film and Media Workshop

---

What We Hide – A Screening of the Feature Film WHAT WE HIDE, followed by a discussion that will highlight how the power of Storytelling can make a difference in addiction education.

**FRIDAY, NOVEMBER 7 | 5:30 PM – 7:00 PM**

**DANIEL KAY, PRESIDENT, TICKLED PICTURES**

*Presenter*

After discovering their mother has fatally overdosed, two scrappy sisters, terrified they'll be separated by an overburdened fostercare system, conceal the body. But as the local police chief, mom's drug counselor, and her volatile ex-boyfriend get closer to uncovering the truth, the girls will have to decide just how far they are willing to go to keep their secret buried.

Authenticity was of paramount importance when developing the film. I collaborated up with Julia Keller, a Pulitzer-prize winning journalist from the Chicago Tribune and we traveled through Ohio, Kentucky, and West Virginia, interviewing folks who have been impacted by the epidemic of addiction. We met with first responders, law enforcement, overwhelmed case workers, and families, including "opioid orphans" – children who had lost both parents to addiction.

The intention from the beginning to raise awareness of the collateral damage caused by addiction, and for the film to be a call-to-arms for the public to become emotionally invested in helping to address the addiction crisis.



# Case Conference

## A Hidden Diagnosis: Prenatal Alcohol Exposure and the Lifelong Psychiatric Sequelae of FASDs

FRIDAY, NOVEMBER 7 | 11:00 AM – 12:30 PM



**ANU BODIA**

*Chairperson*


Anu Bodia is a PGY-4 Psychiatry Resident with a passion for Addiction Psychiatry. She is committed to combining advocacy work with clinical care and is actively involved in Southern California Psychiatric Society. Her goal is to provide compassionate, evidence-based care to individuals struggling with addiction and to advocate for effective treatment solutions.



## DEBRA PINALS, MD

### *Presenter*

DEBRA A. PINALS, MD is Senior Medical and Forensic Advisor, National Association of State Mental Health Program Directors. She holds adjunct clinical professor appointments at the University of Michigan Medical School and Law School. As medical school faculty, she directs the Program in Psychiatry, Law and Ethics. Author of numerous academic and policy-level publications including “Beyond Beds: The Vital Role of the Psychiatric Continuum of Care,” she consults widely regarding behavioral health, crisis response, correctional and forensic services, including her work as an expert consultant to Pew Charitable Trusts. She and her colleagues have also written a forthcoming book, *Addiction and the Law*, published by the American Psychiatric Association Press, to be published in 2024.



## EMILY TEJANI, MD

### *Presenter*

Dr. Emily Tejani is triple board certified in child & adolescent psychiatry, adult psychiatry and addiction medicine. She has a long-standing private practice in Marin County where she specializes in providing individual and family-based consultation and psychotherapy treatment for youth and adults who are experiencing psychiatric and/or substance use disorders. In addition to her private practice, she provides consultation and training through the California Department of Health and Human Services, as well as at the University of California at San Francisco, where she previously helped to develop a Youth and Young Adult Outpatient Substance Use Program. In addition to her clinical work, she has worked as an expert witness on federal opioid litigation, and has been involved in efforts to increase access to psychiatric and addiction treatment services in primary care settings.



## **PANTEA FARAHMAND, MD**

### *Discussants*

Dr. Pantea Farahmand, an Addiction Psychiatrist and Child & Adolescent Psychiatrist at NYU Langone and Associate Program Director of Addiction Psychiatry at NYU, will serve as the Child & Adolescent Psychiatry Panelist. Bio: Addiction Psychiatrist, Child and Adolescent Psychiatrist, NYU Langone. Associate Program Director of Addiction Psychiatry at NYU.



## **INBAL GAFNI, MD**

### *Discussants*

Dr. Inbal Gafni, an Assistant Professor in the Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, and an Addiction Psychiatrist at Women's College Hospital, will serve as Perinatal Psychiatry Discussant.

Inbal Gafni MSc MD FRCPC is an Assistant Professor in the Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, and an Addiction Psychiatrist at Women's College Hospital since 2012. Dr. Gafni completed undergraduate medical and residency training at McMaster University. She then went on to complete an Addiction Psychiatry fellowship at Yale School of Medicine in 2012. Dr. Gafni also has a M.Sc. in psychopharmacology from the University of Toronto. Since 2019, Dr. Gafni has been the Chair of the General Psychiatry Residency Program's Competence Committee at the University of Toronto. In July 2021, she was appointed Assistant Program Director, Curriculum and Assessment, of the General Psychiatry Residency Program. She also serves as the Psychiatry Postgraduate Site Director at Women's College Hospital. Dr. Gafni has a strong interest in medical education (including assessment, curriculum design and teaching about substance use), substance use in the perinatal period, and the interface between trauma and substance use.

# Workshop Session A

THURSDAY, NOVEMBER 6 | 3:45 PM - 5:15 PM

**A1**

**Beyond Induction: Side Effects of Medications for Substance Use Disorders after Initial Period of Treatment – a Master Clinician’s Workshop**

**Chairpersons:** Akhil Anand, MD, Psychiatrist, Jeremy Weleff, DO

**Presenters:** Akhil Anand, MD; Jeremy Weleff, DO; and Muhammad Aadil, MD

**A2**

**Ketamine: The Paradox of Ketamine Addiction and Ketamine as an Emerging Tool for Treatment of Addictions**

**Chairperson:** Madison Buchanan, MD

**Presenters:** Martin Epton, MD, and Emily Tejani, MD

**A3**

**From IV Fentanyl to Dream Engineering: Filling the Evidence Void in the Fentanyl Era through Creativity and Innovation**

**Chairperson:** Pouya Azar, MD

**Presenters:** Andrew Herring, MD, and Pouya Azar, MD

**A4**

**Harm Reduction in Adolescents: What, When, and How?**

**Chairperson:** Brady Heward, MD **Co-Chair:** Peter Jackson, MD

**Presenters:** Jennifer Creedon, MD; Peter Jackson, MD; Anne McBride, MD; and Brady Heward, MD

**A5**

**A Step-by-Step Guide to Forensic Evaluations for Addiction Psychiatrist**

**Chairperson:** Elie Aoun, MD, MRO, FAPA **Co-Chair:** Laurence Westreich, MD

**Presenters:** Carol Weiss, MD and Debra Pinals, MD

# Workshop Session B

---

**FRIDAY, NOVEMBER 7 | 2:00 PM - 3:30 PM**

**B1**

## **Applying the Sequential Intercept Model to Advance Addiction Treatment Across Systems**

**Chairperson:** Jacob Johnson, MD

**Presenters:** Shruti Rajan, MD; Kitt Allenser, CNE; and Mary Taylor, LMFT

**B2**

## **Knowledge and Skills Workshop: Brief Educational Interventions to Reduce Addiction Stigma among Providers and Patients**

**Chairperson:** Alena Balasanova, MD **Co-Chair:** Jeremy Weleff, DO

**Presenters:** Sandra DeJong, MD; Michael Dawes, MD; and Jacob Givens, MD

**B3**

## **Successes and Lessons Learned in Addiction Psychiatry Public Health Initiatives in California**

**Chairperson:** Michael Hoefer, MD

**Presenters:** Timothy Fong, MD; Larissa Mooney, MD; Aaron Meyer, MD; and Jeffrey Devido, MD, FAPA

**B4**

## **Change Starts with the Body: Addressing Interoceptive Dysfunction during Substance Use Disorder Treatment and Recovery**

**Chairperson:** Zev Schuman-Olivier, MD

**Presenters:** Sahib Khalsa, MD, PhD; Wolf Mehling, MD; and Jamie Baik, MD

**B5**

## **The Resistant Patient, The Family in crisis: What to Do when You Get the Call. “Please Help Me Get My Loved One to Enter Treatment for Their Addiction. We Have Tried Everything! Can You help?”**

**Chairperson:** Lisa Goldfarb, MD

**Presenters:** Carrie Wilkens, PhD; Charles Silberstein, MD; Stephen Ross, MD; and Lisa Goldfarb, MD

# Workshop Session C

**SATURDAY, NOVEMBER 8 | 3:45 PM - 5:15 PM**

**C1**

**How to Use Rtms for Comorbid Substance Use Disorder and Major Depressive Disorder: Practical Considerations, Guidelines, Case Discussion**

**Chairperson:** Kathleen Brady, MD **Co-Chair:** Hamed Ekhtiari, MD, PhD

**Presenters:** Victor Tang, MD, MSc, FRCP(C)

**C2**

**Food Addiction in Psychiatric Practice: Emerging Roles for GLP-1 Receptor Agonists**

**Chairpersons:** Muhammad Aadil, MD and Robert Rymowicz, DO

**Presenters:** Ellen Edens, MD, MPE; Justin Young, MD; and David Ross, MD, PhD

**C3**

**Non-Academic Careers in Addiction Psychiatry: Exploring Pathways and Possibilities**

**Chairperson:** Shelby Powers, MD

**Presenters:** Brian Hurley, MD; Sandra Gomez-Luna, FAFA, MD; Danae DiRocco, MD, MPH; Laurence Westreich, MD; and Lauren Grawert, MD

**C4**

**Club Drugs in Rave America: A Clinical and Cultural Perspective**

**Chairperson:** Akhil Anand, MD

**Presenters:** Nora Burns, DO; Eric Dobson, MD; and Akhil Anand, MD

**C5**

**Introduction to EMDR: What is Trauma Response Cycle? How Do We Recognize and Treat Trauma in Our patients?**

**Chairperson:** Lisa Goldfarb, MD, MPH

**Presenters:** Carol Weiss, MD and Lisa Goldfarb, MD, MPH

# Paper Session 1

FRIDAY, NOVEMBER 7 | 3:45 PM - 5:15 PM

## **Modeling the Population-Level Impact of Psychedelic Decriminalization**

**Presenting author:** Jacob Steinle, MD

## **New Onset Pharmacotherapy for Adhd in Adulthood and the Later Risk of Developing Substance Use Disorders: A Retrospective Cohort Study**

**Presenting author:** Vinod Rao, MD, PhD

## **Rising Trends in Suicide and Self-Harm Mortality among U.S. Individuals with Mental and Behavioral Disorders Due to Psychoactive Substance Use (1999-2023)**

**Presenting author:** Humza Saeed, BSc

## **Trends in Urinary Toxicology among Psychiatric Emergency Service Patients: Shifts in Fentanyl and Cocaine Use**

**Presenting author:** Khaled Draghmeh, MD



# Paper Session 2

---

**FRIDAY, NOVEMBER 7 | 3:45 PM - 5:15 PM**

**Religion and Spirituality Moderate the Association between Chronic Pain and Substance Misuse among U.S. Adults at Midlife**

**Presenting author:** Yu-Tien Hsu, MD, PhD

**The Association between Changes in Audit-C Scores and Acute Mental Health Care Utilization over the next Year in a Primary Care Population**

**Presenting author:** Megan Lee, PGY3 Resident

**The Impact of a Brief Personally Tailored Opioid-Overdose and Medication for Opioid Use Disorder Education intervention, Relative to control, on the Acceptance of Naloxone in Peripartum Persons**

**Presenting author:** Michelle Lofwall, MD

**Tracing a Decade of Benzodiazepine Use Prescription Patterns, Discontinuation, and Relapse in a Community Outpatient Addiction Recovery Program**

**Presenting author:** Muhammet Celik, MD

# Paper Session 3

---

**FRIDAY, NOVEMBER 7 | 3:45 PM - 5:15 PM**

**Assessing an ICD-10 Code Approach for Tracking Xylazine-Involved Overdose Deaths in the United States**

**Presenting author:** Joseph Friedman, PhD, MD, MPH

**Assessing the Acceptability of Group Based Psychotherapy for Comorbid PTSD and SUD in Incarcerated Populations**

**Presenting author:** Molly Wooten, MPH, DO

**Finances and Treatment: A Qualitative Study of Pwud in New Haven**

**Presenting Authors:** Razi Kitaneh, MD

**Comparative Effectiveness of Methadone and Buprenorphine-Naloxone in Individuals with a Past-Year Opioid Overdose**

**Presenting author:** Robert Kleinman, MD

# John Renner Award

---

## Medical Student



***Vitor Campus, MD***

Federal University of Santa Catarina



***Khaled Draghmeh, MD***

Yale School of Medicine



***Pryce Michener, BS***

University of Massachusetts Chan Medical School

## PGY I-IV:



***Dipavo Banerjee, MS, DO***

UMass Chan Medical School

# John Renner Award

---



***Anu Bodla, MBBS***

Community Memorial Healthcare Psychiatry  
Residency Program



***Rishab Chawla, MD***

UTHealth Houston Psychiatry Residency



***Heba Ekladios, MD***

Jersey Shore University Medical Center



***Stephanie Foster, MD, PhD***

Brown University General Psychiatry  
Residency Training Program



***Rohit Mukherjee, MD, MPH***

Columbia University

# John Renner Award

---

PGY I-IV:



***Benjamin Shuham, MD***

NYU/ Bellevue Addiction Psychiatry Fellowship Program



***Kathryn Stevens, MD***

Mount Sinai Hospital



***Marlene Torres, MD, MPH***

Yale School of Medicine



***Marcus Vicari, MD, MBE***

Beth Israel Deaconess Medical Center Psychiatry Residency Program



***Jeffrey Wong, MD***

Family Health Centers of San Diego

## Early Career Research Award

---



***Yasna Rostam Abadi, MD, MPH***

Yale University, Psychiatry Residency

## Sheldon Miller Award

---



***Philipa Owusu-Antwi, MD***

Staten Island University Hospital -  
Northwell Health

## Residency Education Awards

---



***Poorvanshi Alag, MD***

Texas Tech University Health Sciences Center



***Oluwole Jegede, MD, MPH***

Yale University School of Medicine

## Regional

---



***Yu-Tien Hsu, MD, PhD***

Yale School of Public Health

## International

---



***Nandhini Ponnuswamy  
Bojappen, MD***

National Institute of Mental Health and  
Neurosciences (NIMHANS), Bengaluru, India



# Promotional Sponsorships

AAAP thanks the following sponsors for their generous support of the 36th Annual Meeting and Scientific Symposium:

## ELI LILLY

Eli Lilly is a medicine company turning science into healing to make life better for people around the world. Eli Lilly provided charging stations.

## NATIONAL INSTITUTE ON DRUG ABUSE

Our mission is to advance science on drug use and addiction and to apply that knowledge to improve individual and public health.

# Exhibitors

---

## BRAEBURN

Braeburn is dedicated to transforming the management of opioid use disorder (OUD) to help people begin and sustain their recovery.

## CALIFORNIA DEPARTMENT OF STATE HOSPITALS

Forensic Mental Health

## CONSTELLATION BEHAVIORAL HEALTH

Constellation Behavioral Health is dedicated to creating innovative treatment programs for adults with mental health, substance use, and co-occurring disorders. We were founded on the belief that excellent treatment outcomes require an intense focus on diagnosing and treating co-occurring disorders and that a treatment program's success ultimately depends on a strong combination of best-in-class clinical and medical care. Our dedicated staff works together to deliver a shared, integrated system of care, providing quality, innovative, and collaborative care at each of our unique Joint Commission-accredited facilities.

## HAZELDEN BETTY FORD FOUNDATION

The Hazelden Betty Ford Foundation is the largest nonprofit addiction recovery organization in the United States. It is also one of the most mission-driven places you will find. The Hazelden Betty Ford Foundation team is passionate about providing hope and ultimately healing. As a living, growing and evolving institution, the Hazelden Betty Ford Foundation is – at our core- a people-powered organization. Hazelden Betty Ford Foundation is comprised of 1600+ employees, seventeen treatment sites and produces \$190 million dollars in annual revenue. This exemplary organization serves nearly 25,000 people annually and is committed to provide hope and healing for those experiencing addiction to alcohol and other drugs.

## CARRARA TREATMENT WELLNESS AND SPA

Carrara luxury rehab centers are unlike anything you expect. Detoxing from drugs and alcohol doesn't mean you need to chain yourself to a dormitory bed. Carrara offers world-class luxury rehabilitation facilities, services, and amenities that exceed your expectations. Our goal is to keep you as comfortable as possible during your stay with us. We understand that when your needs are taken care of, you're more likely to experience a successful recovery

# Exhibitors

---

## MCLEAN HOSPITAL

As an affiliate of Harvard Medical School, McLean Hospital has a direct line to the most cutting-edge medical research in the world. Our treatment options provide the right environment to focus on learning the skills and finding the strength you need to take control of your mental health and your life.

## THE MENNINGER CLINIC

Therapeutic psychiatric services. Committed to enhancing mental healthcare, particularly in underserved areas.

## OPIOID RESPONSE NETWORK, PCSS-MOUD, AAAP

ORN provides education, training and consultation, also known as technical assistance or TA. Every state and territory have designated Technology Transfer Specialists to facilitate this work. These TTS are your local point people who work with you and ORN consultants in your community to meet your TA needs! Our goal is to streamline efforts and fill gaps where needed.

PCSS-MOUD's mission is to increase healthcare providers' knowledge and skills in the prevention, identification, and treatment of substance use disorders with a focus on opioid use disorders.

## PLEOPHARMA, INC

PleoPharma, Inc. is a clinical stage development company in the neuropsychology and addiction space focused on finding solutions for people suffering from cannabis addiction and other cannabis related health problems. PleoPharma's mission is to provide therapies for those individuals seeking treatment for addictions where no FDA approved product or medical treatment exists.

## THE PRACTICE, OC

The Practice, located in Laguna Niguel, CA, is a specialized 6-bed Detox/Residential program exclusively designed for impaired physicians and doctorate-level healthcare professionals

# Exhibitors

---

## PROFESSIONAL RISK MANAGEMENT SERVICES

PRMS® provides psychiatric malpractice insurance with specialized risk management and defense strategies. License defense coverage of \$150,000.\* Telepsychiatry and forensic included. \*May vary by state.

## SEASONS IN MALIBU

A premier provider of luxury dual diagnosis treatment in Southern California, offering personalized programs designed to help individuals regain control and build a healthier future.

## SILVER HILL HOSPITAL

Silver Hill is an independent, not-for-profit psychiatric hospital nationally accredited by the independent Joint Commission. Silver Hill has been a standout among the top psychiatric hospitals in Connecticut and beyond, for adults and adolescents, since our founding in 1931.

## UNIVERSITY OF ARIZONA ADDICTION MEDICINE FELLOWSHIP

The University of Arizona College of Medicine Addiction Medicine Fellowship Program is a one-year, full time fully accredited training program offered by COM-T Department of Psychiatry in conjunction with the Southern Arizona Veterans Administration HealthCare System in Tucson, AZ.

## WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE

West Virginia University has Addiction Medicine and Addiction Psychiatry fellowship positions to train in a comprehensive track that includes work with many populations suffering from SUD and co occurring illnesses.



400 Massasoit Ave STE 108, East Providence, RI 02914

[annual-meeting@aaap.org](mailto:annual-meeting@aaap.org)

[www.aaap.org](http://www.aaap.org)